Shares in Omada Health (NASDAQ:OMDA) rose 21% in their Nasdaq debut on Friday, closing at US$23 after pricing at US$19 in the ...

Weight-loss injections are taking off in Switzerland. But despite obesity being more prevalent among men, it is women who are ...

Fresh from a $150 million IPO on Wall Street, Omada Health CEO Sean Duffy shares his thoughts on speed bumps, GLP-1s, staying ...

After reviewing several large epidemiological studies, clinical trial and in-market data, EMA’s Pharmacovigilance Risk Assessment Committee has concluded non-anterior ischemic optic neuropathy is a ...

Omada Health went public on the Nasdaq Friday, marking the second digital health company to do so after a post-pandemic ...

Treatment should be stopped if nonarteritic anterior ischemic optic neuropathy, which can cause vision loss, is diagnosed.

Omada Health (NASDAQ:OMDA) opened its first day of trading with a bangjumping 21% to $23 after pricing its IPO at $19. That ...

GLP-1s are gaining interest for their impact on weight, blood sugar, and possibly mood in bipolar disorder. Here’s what ...

Omada is trading publicly after 14 years of providing support to patients with weight-related chronic illnesses. Leadership sees the current moment as the perfect time for an IPO, as GLP-1 drugs such ...

GLP-1 drugs alter taste perception… and commonly disrupt the perception of sweetness, bitterness, fatty foods and even ...

The Indianapolis-based drugmaker sees orforglipron as a potential global breakthrough treatment for weight loss and other ...

A new study has found a significant association between the use of GLP-1s such as Ozempic and Wegovy with a higher risk of developing a serious eye condition in patients with diabetes. Here are four t ...